Coherus BioSciences Management to Present at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monac...
April 02 2018 - 9:00AM
Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior
management will be presenting at the H.C. Wainwright Annual Life
Sciences Conference on Tuesday, April 10, 2018 at 8:10 am ET being
held in Monte Carlo, Monaco.
The audio portion of the presentation will be available on the
investors page of the Coherus BioSciences website at
http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global
biosimilar company that develops and commercializes high-quality
therapeutics for major regulated markets. Biosimilars are intended
for use in place of existing, branded biologics to treat a range of
chronic and often life-threatening diseases, with the potential to
reduce costs and expand patient access. Composed of a team of
proven industry veterans with world-class expertise in process
science, analytical characterization, protein production, sales
& marketing and clinical-regulatory development, Coherus is
positioned as a leader in the global biosimilar marketplace.
Coherus is advancing three late-stage clinical products towards
commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420
(adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as
well as developing a robust pipeline of future products in four
therapeutic areas, oncology, immunology (anti-TNF), ophthalmology
including CHS-3351 (ranibizumab biosimilar) and CHS-2020
(aflibercept biosimilar), and CHS-131, a small molecule for
multiple sclerosis. For additional information, please visit
www.coherus.com.
CONTACT:Patrick O'BrienSenior Vice President, Investor
RelationsCoherus BioSciences, Inc.pobrien@coherus.com+1 (650)
649-3527
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Sep 2023 to Sep 2024